AutoImmune-AIMM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AutoImmune-AIMM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (100)	4/29/1997 11:39:00 AM
From: Mel Kaplan	of 298

John, as a retired immunologist, I can agree with you to this extent. The Myloral failure is not necessarily an indication that oral tolerance does not work. Several hypotheses can be proposed: the antigen myelin basic protein (MBT) was inadequate, other myelin antigens as proteolipid-protein were excluded, autoimmunity to MBT as an experimental model for MS may be a secondary phenomenon in pathogenesis. I agree that the rheumatoid athritis trials may be more appropriate for oral tolerance to type II collagen(colloral) . Autoimmune bodies and collagen- bound Ig's in rheumatoid tissues have been reported. Preliminary reports in U.S. and Germany have indicated a selective responsiveness to oral type II collagen. The goal of the colloral trials may be to characterize the responsive patients. Trials with juvenile diabetes are in progress. All in all, I regard AIMM as a speculation that is worth-while. Mel

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next